Connaught Labs' acellular pertusis vaccine
PLA filed for bivalent acellular vaccine, firm said Jan. 11, for innoculation at 18 months of age. The vaccine, licensed for the U.S. from Biken, Japan, was studied in Japan and Sweden on children from three months to two years old and in U.S. trials in 18-month olds. Connaught said it is continuing to conduct studies in infants 2-6 months old, "but feels current results warrant" the PLA filing for 18-month olds.
You may also be interested in...
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?